TP
MRNA icon

Theleme Partners’s Moderna MRNA Stock Holding History

Theleme Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,972
Closed -$53.3M – 13
2024
Q3 		$53.3M Buy
7,972
+1,768
+28% +$162K 3.05% 9
2024
Q2 		$73.7M Sell
6,204
-1,433,796
-100% -$181M 3.54% 8
2024
Q1 		$153M Sell
1,440,000
-574,000
-29% -$57.9M 7.78% 4
2023
Q4 		$200M Buy
+2,014,000
New +$169M 9.55% 4
2023
Q1 		– Sell
-282,000
Closed -$50.7M – 12
2022
Q4 		$50.7M Buy
+282,000
New +$46.1M 1.91% 10

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Theleme Partners's MRNA Position: Q2 2026 in Review

Theleme Partners increased its Moderna (MRNA) stake by 0.12% in Q2 2026, buying an estimated $483K and bringing the position to 8,057,571 shares worth $564M. The position accounts for 33.52% of the portfolio, ranked #1.

Theleme Partners first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.52B in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Theleme Partners held 8,057,571 shares of Moderna worth $564M as of Q2 2026.
  • Theleme Partners bought 9,326 Moderna shares in Q2 2026, an estimated $483K.
  • Moderna made up 33.52% of Theleme Partners's portfolio in Q2 2026, its #1 holding.
  • Theleme Partners first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
  • Theleme Partners's Moderna position peaked at $1.52B in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Theleme Partners's 13F filing for Q2 2026, filed 13 Aug 2026.